$IRON News

Disc Medicine: The CRL Has Created A Cleaner Bull Case

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $85

Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript

Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook - Slideshow

Wedbush Reiterates Outperform on Disc Medicine, Maintains $88 Price Target

Disc Medicine Completes FDA Type A Meeting Regarding The Complete Response Letter To The New Drug Application For Bitopertin In Erythropoietic Protoporphyria; Data From APOLLO Phase 3 Study Expected In Q4 2026

Disc Medicine Presents Updated Data From Myelofibrosis And Anemia Treatment RALLY-MF Phase 2 Trial Showing Reductions In Hepcidin And Higher Iron Levels, A Positive Clinical Impact On Anemia Measures Across A Broad Range Of Patient Types

Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $80

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Disc Medicine to Participate in Upcoming Investor Conferences

A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

Disc Medicine Q1 EPS $(1.65) Beats $(1.73) Estimate

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting

Disc Medicine To Present Data From RALLY-MF Phase 2 Trial Of DISC-0974 In Anemia Of Myelofibrosis In Oral Abstract Session At ASCO Annual Meeting

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria

Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals

Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $79